Assembly Biosciences Inc (ASMB) - Total Liabilities
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has total liabilities worth $25.18 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Assembly Biosciences Inc (ASMB) investment intensity to see how much of total assets are deployed in long-term investments.
Assembly Biosciences Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ASMB asset base.
Assembly Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Assembly Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
China | CN¥5.83 Billion |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
China | CN¥259.79 Million |
|
Zhongyan Technology Co Ltd
SHE:003001
|
China | CN¥453.43 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥656.81 Million |
|
Bhakti Multi Artha Pt
JK:BHAT
|
Indonesia | Rp604.80 Billion |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
India | Rs16.14 Billion |
|
PlayAGS Inc
NYSE:AGS
|
USA | $592.31 Million |
|
Shanghai Metersbonwe Fashion&Accessories Co Ltd
SHE:002269
|
China | CN¥1.60 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Assembly Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ASMB equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Assembly Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Assembly Biosciences Inc (2008–2025)
The table below shows the annual total liabilities of Assembly Biosciences Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.84 Million | -40.75% |
| 2024-12-31 | $85.81 Million | -10.36% |
| 2023-12-31 | $95.73 Million | +400.40% |
| 2022-12-31 | $19.13 Million | -13.56% |
| 2021-12-31 | $22.13 Million | -48.14% |
| 2020-12-31 | $42.68 Million | -42.85% |
| 2019-12-31 | $74.67 Million | +30.10% |
| 2018-12-31 | $57.39 Million | +2.15% |
| 2017-12-31 | $56.18 Million | +208.01% |
| 2016-12-31 | $18.24 Million | +21.58% |
| 2015-12-31 | $15.00 Million | +18.56% |
| 2014-12-31 | $12.65 Million | +379.67% |
| 2013-12-31 | $2.64 Million | -3.91% |
| 2012-12-31 | $2.75 Million | +9.25% |
| 2011-12-31 | $2.51 Million | -15.96% |
| 2010-12-31 | $2.99 Million | -77.90% |
| 2009-12-31 | $13.53 Million | +31.00% |
| 2008-12-31 | $10.33 Million | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more